I-Mab is a global biotech company focused on developing biologics, specifically highly differentiated immunotherapies, to treat various cancers. Their pipeline includes bispecific antibodies and monoclonal antibodies designed to enhance immune response against tumor cells, addressing the need for more effective cancer treatments.
Funding
$418M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers lack effective treatments, necessitating the development of novel immunotherapies that can enhance the body's immune response against tumor cells. Current treatment options may not be effective for all patients, and there is a need for more targeted and differentiated biologics.
Solution
I-Mab is a biopharmaceutical company focused on developing highly differentiated immunotherapies for cancer treatment. The company's pipeline includes bispecific antibodies and monoclonal antibodies engineered to stimulate the immune system to target and destroy cancer cells. I-Mab's approach centers on precision immuno-oncology, aiming to create agents that offer improved efficacy and safety profiles. Their therapeutic candidates are designed to address unmet needs in various cancer types by transforming scientific potential into tangible treatments.
Target Audience
The primary target audience includes patients with various cancers who require more effective and targeted treatment options, as well as healthcare providers seeking innovative immunotherapies.
Features
- Development of bispecific antibodies to simultaneously target two different molecules on cancer cells and immune cells
- Monoclonal antibody development to enhance immune response against tumors
- Focus on precision immuno-oncology for targeted cancer therapies
- Pipeline includes Uliledlimab (CD73 antibody), Givastomig (Claudin 18.2 x 4-1BB bispecific antibody), and Ragistomig (PD-L1 x 4-1BB bispecific antibody)